146 related articles for article (PubMed ID: 38399618)
41. Long-term Use of Proton Pump Inhibitors Is Associated With Increased Microbial Product Translocation, Innate Immune Activation, and Reduced Immunologic Recovery in Patients With Chronic Human Immunodeficiency Virus-1 Infection.
Serpa JA; Rueda AM; Somasunderam A; Utay NS; Lewis D; Couturier JP; Breaux KG; Rodriguez-Barradas M
Clin Infect Dis; 2017 Oct; 65(10):1638-1643. PubMed ID: 29020215
[TBL] [Abstract][Full Text] [Related]
42. Brief Report: Systemic Inflammation, Immune Activation, and Impaired Lung Function Among People Living With HIV in Rural Uganda.
North CM; Muyanja D; Kakuhikire B; Tsai AC; Tracy RP; Hunt PW; Kwon DS; Christiani DC; Okello S; Siedner MJ
J Acquir Immune Defic Syndr; 2018 Aug; 78(5):543-548. PubMed ID: 29683991
[TBL] [Abstract][Full Text] [Related]
43. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
[TBL] [Abstract][Full Text] [Related]
44. Antiretroviral drug class and anaemia risk in the current treatment era among people living with HIV in the USA: a clinical cohort study.
Harding BN; Whitney BM; Nance RM; Crane HM; Burkholder G; Moore RD; Mathews WC; Eron JJ; Hunt PW; Volberding P; Rodriguez B; Mayer K; Saag MS; Kitahata MM; Heckbert SR; Delaney JAC
BMJ Open; 2020 Mar; 10(3):e031487. PubMed ID: 32198297
[TBL] [Abstract][Full Text] [Related]
45. Unchanged Levels of Soluble CD14 and IL-6 Over Time Predict Serious Non-AIDS Events in HIV-1-Infected People.
Sunil M; Nigalye M; Somasunderam A; Martinez ML; Yu X; Arduino RC; Utay NS; Bell TK
AIDS Res Hum Retroviruses; 2016 Dec; 32(12):1205-1209. PubMed ID: 27344921
[TBL] [Abstract][Full Text] [Related]
46. Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy.
Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Huang SH; Huang YC; Su YC; Liu WC; Hung CC
Int J Infect Dis; 2021 Apr; 105():147-151. PubMed ID: 33592339
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of several serum interleukins as markers for treatment effectiveness in naïve HIV infected patients: A pilot study.
Jianu C; Itu-Mureşan C; Drugan C; Filipescu I; Topan AV; Jianu ME; Morar II; Bolboacă SD
PLoS One; 2021; 16(11):e0260007. PubMed ID: 34784398
[TBL] [Abstract][Full Text] [Related]
48. Therapeutic Drug Monitoring of HIV Antiretroviral Drugs in Pregnancy: A Narrative Review.
O'Kelly B; Murtagh R; Lambert JS
Ther Drug Monit; 2020 Apr; 42(2):229-244. PubMed ID: 32004247
[TBL] [Abstract][Full Text] [Related]
49. Convenience, efficacy, safety, and durability of INSTI-based antiretroviral therapies: evidence from the Italian MaSTER cohort.
Rich SN; Nasta P; Quiros-Roldan E; Fusco P; Tondinelli A; Costa C; Fornabaio C; Mazzini N; Prosperi M; Torti C; Carosi G;
Eur J Med Res; 2023 Aug; 28(1):292. PubMed ID: 37596688
[TBL] [Abstract][Full Text] [Related]
50. Comparative effectiveness of antiretroviral drug classes for the treatment of HIV infection in patients with high viral loads: a multicentre retrospective cohort study.
Adams JL; Murray M; Patel N; Sawkin MT; Boardman RC; Pham C; Kaur H; Patel D; Yager JL; Pontiggia L; Baxter J
HIV Med; 2021 Jan; 22(1):28-36. PubMed ID: 32964664
[TBL] [Abstract][Full Text] [Related]
51. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
[TBL] [Abstract][Full Text] [Related]
52. New onset type 2 diabetes mellitus risks with integrase strand transfer inhibitors-based regimens: A systematic review and meta-analysis.
Kajogoo VD; Amogne W; Medhin G
Metabol Open; 2023 Mar; 17():100235. PubMed ID: 36923992
[TBL] [Abstract][Full Text] [Related]
53. Real-World Assessment of Weight Change in African American Females and Hispanics with HIV-1 After Initiating Integrase Strand-Transfer Inhibitors or Protease Inhibitors.
Chen YW; Anderson D; Pericone CD; Donga P
J Health Econ Outcomes Res; 2022; 9(1):1-10. PubMed ID: 35083364
[No Abstract] [Full Text] [Related]
54. CXCL13 as a Biomarker of Immune Activation During Early and Chronic HIV Infection.
Mehraj V; Ramendra R; Isnard S; Dupuy FP; Lebouché B; Costiniuk C; Thomas R; Szabo J; Baril JG; Trottier B; Coté P; LeBlanc R; Durand M; Chartrand-Lefebvre C; Kema I; Zhang Y; Finkelman M; Tremblay C; Routy JP
Front Immunol; 2019; 10():289. PubMed ID: 30846990
[No Abstract] [Full Text] [Related]
55. A Low Frequency of IL-17-Producing CD8
Perdomo-Celis F; Feria MG; Taborda NA; Rugeles MT
Front Immunol; 2018; 9():2502. PubMed ID: 30420859
[TBL] [Abstract][Full Text] [Related]
56. Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infection.
Veil R; Poizot-Martin I; Reynes J; Goujard C; Seng R; Delobel P; Cotte L; Duvivier C; Rey D; Tran L; Surgers L; Allavena C; Lascoux Combe C; Cheret A; Meyer L
AIDS; 2020 Mar; 34(4):493-500. PubMed ID: 31764069
[TBL] [Abstract][Full Text] [Related]
57. Switch rates, time-to-switch, and switch patterns of antiretroviral therapy in people living with human immunodeficiency virus in Japan, in a hospital-claim database.
Ruzicka DJ; Kuroishi N; Oshima N; Sakuma R; Naito T
BMC Infect Dis; 2019 Jun; 19(1):505. PubMed ID: 31182050
[TBL] [Abstract][Full Text] [Related]
58. Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens.
Maggi P; Ricci ED; Cicalini S; Pellicanò GF; Celesia BM; Vichi F; Cascio A; Sarchi E; Orofino G; Squillace N; Madeddu G; De Socio GV; Bargiacchi O; Molteni C; Masiello A; Saracino A; Menzaghi B; Falasca K; Taramasso L; Di Biagio A; Bonfanti P
BMC Infect Dis; 2023 Apr; 23(1):227. PubMed ID: 37059996
[TBL] [Abstract][Full Text] [Related]
59. Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy.
Gagliardini R; Gianotti N; Maggiolo F; Cozzi-Lepri A; Antinori A; Nozza S; Lapadula G; De Luca A; Mussini C; Gori A; Saracino A; Andreoni M; Monforte AD;
Int J Antimicrob Agents; 2021 Oct; 58(4):106406. PubMed ID: 34293454
[TBL] [Abstract][Full Text] [Related]
60. Effect of Combined Antiretroviral Therapy on the Levels of Selected Parameters Reflecting Metabolic and Inflammatory Disturbances in HIV-Infected Patients.
Jurkowska K; Szymańska B; Knysz B; Piwowar A
J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35330038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
